Decoy Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $622.40K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2025 Ended Jun 30, 2025 | Jul 31, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 17, 2025 | After market close | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 10, 2023 | After market close | – | $-1.43 | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 10, 2022 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 15, 2022 | After market close | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 12, 2022 | After market close | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 10, 2022 | After market close | – | – | – |
| Q2 FY2021 Ended Jun 30, 2021 | Aug 5, 2021 | After market close | – | – | – |
| Q1 FY2021 Ended Mar 31, 2021 | May 12, 2021 | After market close | – | – | – |
| Q3 FY2020 Ended Sep 30, 2020 | Nov 12, 2020 | Before market open | – | – | – |
| Q2 FY2020 Ended Jun 30, 2020 | Jul 29, 2020 | After market close | – | – | – |
| Q1 FY2020 Ended Mar 31, 2020 | May 14, 2020 | After market close | – | – | – |
Press releases
Announcements Decoy Therapeutics filed with the SEC
Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Other events · EX-99.1 to Form 8-K
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
Other events · EX-99.1 to Form 8-K
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Other events · EX-99.1 to Form 8-K
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Other events · EX-99.1 to Form 8-K
Three and six months ended June 30, 2025, 2024 (unaudited) and year end December 31, 2024
Other events · EX-99.2 to Form 8-K
UNAUDITED PRO FORMA CONSOLIDATED COMBINED FINANCIAL INFORMATION
Other events · EX-99.3 to Form 8-K
Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard
Other events · EX-99.1 to Form 8-K
Consolidated Financial Statements Years Ended December 31, 2023 and 2022
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Consolidated Financial Statements Nine months ended September 30, 2024 and 2023
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
UNAUDITED PRO FORMA CONSOLIDATED COMBINED FINANCIAL INFORMATION
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
Executive or director change · Other events · EX-99.1 to Form 8-K
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Salarius Pharmaceuticals Announces $6 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders
Other events · EX-99.1 to Form 8-K
Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5 th Annual Targeted Protein Degradation Conference
Other events · EX-99.1 to Form 8-K
Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement
Other events · EX-99.1 to Form 8-K
Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K